Literature DB >> 21705151

Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma.

Amaury Paumier1, Mithra Ghalibafian, Jennifer Gilmore, Anne Beaudre, Pierre Blanchard, Mohammed el Nemr, Farez Azoury, Hweej al Hamokles, Dimitri Lefkopoulos, Theodore Girinsky.   

Abstract

PURPOSE: To assess the additional benefits of using the deep-inspiration breath-hold (DIBH) technique with intensity-modulated radiotherapy (IMRT) in terms of the protection of organs at risk for patients with mediastinal Hodgkin's disease. METHODS AND MATERIALS: Patients with early-stage Hodgkin's lymphoma with mediastinal involvement were entered into the study. Two simulation computed tomography scans were performed for each patient: one using the free-breathing (FB) technique and the other using the DIBH technique with a dedicated spirometer. The clinical target volume, planning target volume (PTV), and organs at risk were determined on both computed tomography scans according to the guidelines of the European Organization for Research and Treatment of Cancer. In both cases, 30 Gy in 15 fractions was prescribed. The dosimetric parameters retrieved for the statistical analysis were PTV coverage, mean heart dose, mean coronary artery dose, mean lung dose, and lung V20.
RESULTS: There were no significant differences in PTV coverage between the two techniques (FB vs. DIBH). The mean doses delivered to the coronary arteries, heart, and lungs were significantly reduced by 15% to 20% using DIBH compared with FB, and the lung V20 was reduced by almost one third. The dose reduction to organs at risk was greater for masses in the upper part of the mediastinum. IMRT with DIBH was partially implemented in 1 patient. This combination will be extended to other patients in the near future.
CONCLUSIONS: Radiation exposure of the coronary arteries, heart, and lungs in patients with mediastinal Hodgkin's lymphoma was greatly reduced using DIBH with IMRT. The greatest benefit was obtained for tumors in the upper part of the mediastinum. The possibility of a wider use in clinical practice is currently under investigation in our department. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21705151     DOI: 10.1016/j.ijrobp.2011.05.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.

Authors:  Jan Kriz; Max Spickermann; Philipp Lehrich; Heinz Schmidberger; Gabriele Reinartz; Hans Eich; Uwe Haverkamp
Journal:  Strahlenther Onkol       Date:  2015-04-16       Impact factor: 3.621

Review 2.  Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

Authors:  Andrea Riccardo Filippi; Mario Levis; Rahul Parikh; Bradford Hoppe
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 3.  Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma.

Authors:  Victor J Gonzalez
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

4.  Hodgkin lymphoma, version 2.2015.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

5.  Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.

Authors:  Chelsea C Pinnix; Grace L Smith; Sarah Milgrom; Eleanor M Osborne; Jay P Reddy; Mani Akhtari; Valerie Reed; Isidora Arzu; Pamela K Allen; Christine F Wogan; Michele A Fanale; Yasuhiro Oki; Francesco Turturro; Jorge Romaguera; Luis Fayad; Nathan Fowler; Jason Westin; Loretta Nastoupil; Fredrick B Hagemeister; M Alma Rodriguez; Sairah Ahmed; Yago Nieto; Bouthaina Dabaja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-01       Impact factor: 7.038

Review 6.  Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.

Authors:  Stephanie A Terezakis; Yvette L Kasamon
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-29       Impact factor: 6.312

Review 7.  Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?

Authors:  Frank Lohr; Dietmar Georg; Luca Cozzi; Hans Theodor Eich; Damien C Weber; Julia Koeck; Barbara Knäusl; Karin Dieckmann; Yasser Abo-Madyan; Christian Fiandra; Rolf-Peter Mueller; Andreas Engert; Umberto Ricardi
Journal:  Strahlenther Onkol       Date:  2014-09-11       Impact factor: 3.621

Review 8.  Evolution of the techniques of radiation therapy in the management of lymphoma.

Authors:  Richard T Hoppe
Journal:  Int J Clin Oncol       Date:  2013-04-11       Impact factor: 3.402

Review 9.  Cardiotoxicity of mediastinal radiotherapy.

Authors:  Ivica Ratosa; Maja Ivanetic Pantar
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-30

10.  Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.

Authors:  Sachin R Jhawar; Zorimar Rivera-Núñez; Richard Drachtman; Peter D Cole; Bradford S Hoppe; Rahul R Parikh
Journal:  JAMA Oncol       Date:  2019-05-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.